geron - GERN
GERN
Close Chg Chg %
1.56 0.04 2.24%
Open Market
1.60
+0.04 (2.24%)
Volume: 4.96M
Last Updated:
Jun 6, 2025, 12:34 PM EDT
Company Overview: geron - GERN
GERN Key Data
| Open $1.59 | Day Range 1.56 - 1.63 |
| 52 Week Range 1.17 - 5.34 | Market Cap $993.59M |
| Shares Outstanding 636.92M | Public Float 603.40M |
| Beta 0.69 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.21 |
| Yield 0.00% | Dividend $0.15 |
| EX-DIVIDEND DATE Jul 22, 2014 | SHORT INTEREST N/A |
| AVERAGE VOLUME 12.77M |
GERN Performance
| 1 Week | 1.32% | ||
| 1 Month | 30.51% | ||
| 3 Months | -10.98% | ||
| 1 Year | -66.45% | ||
| 5 Years | 0.00% |
GERN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About geron - GERN
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
GERN At a Glance
Geron Corp.
919 East Hillsdale Boulevard
Foster City, California 94404
| Phone | 1-650-473-7700 | Revenue | 76.99M | |
| Industry | Biotechnology | Net Income | -174,572,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 32,386.92% | |
| Fiscal Year-end | 12 / 2025 | Employees | 229 | |
| View SEC Filings |
GERN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 29.703 |
| Price to Book Ratio | 7.658 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.318 |
| Enterprise Value to Sales | 27.60 |
| Total Debt to Enterprise Value | 0.116 |
GERN Efficiency
| Revenue/Employee | 336,218.341 |
| Income Per Employee | -762,323.144 |
| Receivables Turnover | 1.984 |
| Total Asset Turnover | 0.156 |
GERN Liquidity
| Current Ratio | 5.561 |
| Quick Ratio | 5.122 |
| Cash Ratio | 4.626 |
GERN Profitability
| Gross Margin | 98.369 |
| Operating Margin | -225.644 |
| Pretax Margin | -226.735 |
| Net Margin | -226.735 |
| Return on Assets | -35.319 |
| Return on Equity | -66.092 |
| Return on Total Capital | -33.136 |
| Return on Invested Capital | -44.112 |
GERN Capital Structure
| Total Debt to Total Equity | 87.938 |
| Total Debt to Total Capital | 46.791 |
| Total Debt to Total Assets | 41.468 |
| Long-Term Debt to Equity | 80.324 |
| Long-Term Debt to Total Capital | 42.739 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Geron - GERN
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.39M | 596.00K | 237.00K | 76.99M | |
Sales Growth
| +450.59% | -57.21% | -60.23% | +32,386.92% | |
Cost of Goods Sold (COGS) incl D&A
| 783.00K | 868.00K | 1.03M | 1.26M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 783.00K | 868.00K | 1.03M | 1.22M | |
Depreciation
| 783.00K | 868.00K | 1.03M | 1.22M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | +10.86% | +19.01% | +21.59% | |
Gross Income
| 610.00K | (272.00K) | (796.00K) | 75.74M | |
Gross Income Growth
| - | -144.59% | -192.65% | +9,614.82% | |
Gross Profit Margin
| +43.79% | -45.64% | -335.86% | +98.37% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 114.61M | 138.28M | 193.15M | 249.47M | |
Research & Development
| 85.73M | 95.52M | 125.05M | 103.74M | |
Other SG&A
| 28.88M | 42.76M | 68.10M | 145.73M | |
SGA Growth
| +50.34% | +20.65% | +39.68% | +29.16% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 1.71M | - |
EBIT after Unusual Expense
| (114.00M) | (138.55M) | (193.94M) | (175.44M) | |
Non Operating Income/Expense
| 1.63M | 3.53M | 18.13M | 19.37M | |
Non-Operating Interest Income
| 527.00K | 2.53M | 18.15M | 19.61M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 3.74M | 6.88M | 8.31M | 18.50M | |
Interest Expense Growth
| +392.11% | +84.01% | +20.78% | +122.62% | |
Gross Interest Expense
| 3.74M | 6.88M | 8.31M | 18.50M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (116.11M) | (141.90M) | (184.13M) | (174.57M) | |
Pretax Income Growth
| -53.55% | -22.21% | -29.76% | +5.19% | |
Pretax Margin
| -8,335.39% | -23,808.89% | -77,690.72% | -226.73% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (116.11M) | (141.90M) | (184.13M) | (174.57M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (116.11M) | (141.90M) | (184.13M) | (174.57M) | |
Net Income Growth
| -53.55% | -22.21% | -29.76% | +5.19% | |
Net Margin Growth
| -8,335.39% | -23,808.89% | -77,690.72% | -226.73% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (116.11M) | (141.90M) | (184.13M) | (174.57M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (116.11M) | (141.90M) | (184.13M) | (174.57M) | |
EPS (Basic)
| -0.3544 | -0.3726 | -0.3227 | -0.2702 | |
EPS (Basic) Growth
| -27.21% | -5.14% | +13.39% | +16.27% | |
Basic Shares Outstanding
| 327.63M | 380.78M | 570.65M | 646.03M | |
EPS (Diluted)
| -0.3544 | -0.3726 | -0.3227 | -0.2702 | |
EPS (Diluted) Growth
| -27.21% | -5.14% | +13.39% | +16.27% | |
Diluted Shares Outstanding
| 327.63M | 380.78M | 570.65M | 646.03M | |
EBITDA
| (113.22M) | (137.68M) | (192.91M) | (172.51M) | |
EBITDA Growth
| -49.01% | -21.61% | -40.11% | +10.57% | |
EBITDA Margin
| -8,127.49% | -23,101.01% | -81,397.05% | -224.06% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 3.688 | |
| Number of Ratings | 9 | Current Quarters Estimate | -0.028 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | -0.127 | |
| Last Quarter’s Earnings | -0.03 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.27 | Next Fiscal Year Estimate | -0.044 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 9 | 9 |
| Mean Estimate | -0.03 | -0.03 | -0.13 | -0.04 |
| High Estimates | -0.01 | -0.01 | -0.06 | 0.06 |
| Low Estimate | -0.04 | -0.05 | -0.18 | -0.11 |
| Coefficient of Variance | -35.43 | -45.73 | -33.59 | -134.71 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 6 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 3 | 3 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Geron - GERN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Geron - GERN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 3, 2025 | John A. Scarlett Chairman, President and CEO; Director | 12,500 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.76 per share | 22,000.00 |
| Mar 3, 2025 | Scott Alan Samuels EVP, Chief Legal Officer | 26,682 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.61 per share | 42,958.02 |
| Mar 3, 2025 | Jim Ziegler EVP, Chief Commercial Officer | 100,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.6 per share | 160,000.00 |
| Feb 21, 2025 | Andrew J. Grethlein EVP, Chief Operating Officer | 140,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 21, 2025 | John A. Scarlett Chairman, President and CEO; Director | 410,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 21, 2025 | Andrew J. Grethlein EVP, Chief Operating Officer | 839,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 21, 2025 | Scott Alan Samuels EVP, Chief Legal Officer | 104,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 21, 2025 | Jim Ziegler EVP, Chief Commercial Officer | 89,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 21, 2025 | Michelle Robertson EVP, Chief Financial Officer | 656,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 21, 2025 | Michelle Robertson EVP, Chief Financial Officer | 110,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 11, 2024 | Andrew J. Grethlein EVP, Chief Operating Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 11, 2024 | Andrew J. Grethlein EVP, Chief Operating Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 13, 2024 | Faye Feller EVP, Chief Medical Officer | 87,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 13, 2024 | Faye Feller EVP, Chief Medical Officer | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.63 per share | 0.00 |
| Jun 13, 2024 | Faye Feller EVP, Chief Medical Officer | 155,400 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.3 per share | 202,020.00 |
| Jun 13, 2024 | Faye Feller EVP, Chief Medical Officer | 20,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.06 per share | 21,200.00 |
| Jun 13, 2024 | Faye Feller EVP, Chief Medical Officer | 112,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.06 per share | 119,250.00 |
| Jun 13, 2024 | Anil Kapur EVP, Corp Strategy & CCO | 328,125 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 13, 2024 | Anil Kapur EVP, Corp Strategy & CCO | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.64 per share | 0.00 |
| Jun 13, 2024 | Anil Kapur EVP, Corp Strategy & CCO | 421,875 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.06 per share | 447,187.50 |